Home › Funds › Catalio Capital Management, LP › BBOT
Catalio Capital Management, LP position in BBOT
BridgeBio Oncology Therapeutic Inc · Health Care
Catalio Capital Management, LP reported holding 318,407 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$2.4M, representing 0.46% of its reported portfolio and ranking #33 among its reported holdings. Catalio Capital Management, LP first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Catalio Capital Management, LP's BBOT position evolved
Catalio Capital Management, LP first disclosed a stake in BBOT in Q2 2026 at 318,407 shares (US$2.4M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 318.41K | $2.43M | New |
About BBOT and 13F data
BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Omega Fund Management, LLC (US$25.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBOT
- Cormorant Asset Management, LP 17.88M sh · $136.23M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.89M sh · $37.23M · Q2 2026
- Omega Fund Management, LLC 3.29M sh · $25.07M · Q2 2026
- Alphabet Inc. 2.82M sh · $21.51M · Q2 2026
- EcoR1 Capital, LLC 2.82M sh · $21.51M · Q2 2026
- Enavate Sciences GP, LLC 2.63M sh · $20.02M · Q2 2026
- Novo Holdings A/S 2.25M sh · $17.14M · Q2 2026
- Laurion Capital Management LP 2.00M sh · $15.26M · Q2 2026
- Aisling Capital Management LP 1.02M sh · $7.76M · Q2 2026
- Opaleye Management Inc. 700.00K sh · $5.33M · Q2 2026
- Casdin Capital 282.31K sh · $2.15M · Q2 2026
- Avidity Partners Management LP 43.85K sh · $334.16K · Q2 2026
More on Catalio Capital Management, LP
FAQ
How long has Catalio Capital Management, LP held BBOT?
Catalio Capital Management, LP has disclosed BBOT holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Catalio Capital Management, LP's current position in BBOT?
As of Q2 2026, Catalio Capital Management, LP holds 318.41K shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $2.43M, representing 0.46% of its reported portfolio and ranking #33.
Has Catalio Capital Management, LP been buying or selling BBOT?
In the latest 13F filing (Q2 2026), Catalio Capital Management, LP newly opened its position in BBOT.
Which other funds hold BBOT?
Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Omega Fund Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.